PLXConference•prnewswire•
Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Sentiment:Negative (30)
Summary
(PLX) CARMIEL, Israel, Sept. 2, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by prnewswire